ADCYAP1 and Hypoglycemia: Several studies have explored the antidiabetic potential of PACAP due to the modulation of glucose-induced insulin secretion, the proliferation of islet cell mass, and increased glucagon response to insulin-induced hypoglycemia [47,48,49].